Background: Μonoclonal antibodies have been proposed as a novel therapy in patients suffering from chronic rhinosinusitis with nasal polyposis (CRSwNP). The purpose of this systematic review was to evaluate their efficacy and safety.
Introduction
Chronic rhinosinusitis (CRS) is a complex disease, affecting approximately 11,9% and 10,9% of the general population in the United States and Europe respectively (1, 2) . According to the European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS), CRS is characterized by the presence of both subjective and objective evidence of chronic sinonasal inflammation for more than 12 weeks (3) and includes several distinguished clinical entities, the most important of which are CRS with nasal polyposis (CRSwNP) and CRS without nasal polyposis (CRSsNP) (4) . CRSwNP is a debilitating disease that has a substantial impact on the patient's quality of life with its overall annual economic burden in the United States to be estimated around $22 billion in 2014 (direct and indirect costs) (5) . Despite the fact that its etiology remains elusive, CRSwNP is often associated with allergy, asthma, infection, fungi, cystic fibrosis, and aspirin sensitivity (3) .
The connection between CRSwNP and bronchial asthma has been extensively investigated by numerous studies, with the co-incidence of CRSwNP and asthma to be about 20-70% (6) (7) (8) .The comparison between patients suffering from both CRSwNP and asthma and those without asthma has proved that high levels of eosinophil cationic protein (ECP), IgE and Staphylococcus aureus enterotoxin IgE (SE-IgE) in the nasal polyps are substantially associated with asthma comorbidity (8) . Furthermore, increased levels of IgE, SE-IgE, IL-5 and ECP are also linked with a more seriοus form of CRSwNP with more frequent recurrence after surgery (9) .
The strong connection of nasal polyposis and asthma combined with the encouraging results of biologic therapy in patients suffering from asthma motivated researchers to conduct studies evaluating the potential use of different monoclonal antibodies in a subgroup of patients mainly suffering from nasal polyposis and comorbid asthma. Three main biological therapies have been assessed regarding their efficacy and safety in adult patients with CRSwNP: Omalizumab is an anti-IgE monoclonal antibody approved in the European Union and the United States for the treatment of severe allergic asthma (10) . Considering the high total IgE levels in nasal secretions, polyp tissue, and serum of patients with CRSwNP combined with their relevance in patients with allergic asthma, omalizumab has been assessed as a potential treatment in the subgroup of patients with CRSwNP and comorbid asthma. Furthermore, prominent eosinophilia is characteristic in more than 80% of Caucasian patients with CRSwNP (11) . IL-5 is a key mediator in chemotaxis, differentiation, activation, and survival of eosinophils and is detected in high levels in patients with CRSwNP (12, 13) . Hence, preventing free circulating IL-5 from binding to the IL-5R subunit a (IL-5Ra) expressed on the surface of eosinophils has been proposed as a new treatment strategy in these patients. For this purpose, two different monoclonal antibodies have been evaluated, reslizumab and mepolizumab (14) . Lastly, dupilumab is a human monoclonal antibody (mAb) that binds to the IL-4 receptor alpha subunit (IL-4Rα) inhibiting signaling of both IL-4 and IL-13 (15) , two type 2 helper T-cell (Th2) associated cytokines that play a major role in the pathogenesis of nasal polyposis. This type of biologic therapy has previously shown clinical benefit in patients with asthma and atopic dermatitis and could not have been omitted in the research of nasal polyposis (16, 17) .
The aim of this study is to review all existing evidence concerning the efficacy and safety of monoclonal antibodies used for the treatment of adults with chronic rhinosinusitis with nasal polypοsis. Finally, researchers contacted pharmaceutical companies and experts via e-mail in order to obtain unpublished work. No time or language limitation was applied. As this study was a systemic review of published articles, neither informed consent nor ethics approval was required.
Methods

Search strategy
Selection of studies
The study selection process was carried out independently by the two reviewers and disagreements were resolved by consensus. The inclusion and exclusion criteria of studies in this systematic review were specified prior to the literature search.
Any studies that met the following criteria were eligible for inclusion: 1) randomized controlled trials (RCTs) comparing the use of monoclonal antibodies therapy with placebo or another therapy 
Data extraction and quality assessment
Two reviewers (NT and DD) independently reviewed each study according to the predefined criteria for eligibility, and, finally, extracted data. Any disagreement in the process of study selection or data extraction was resolved through consensus. A predefined form was used to extract data from each study. The identified. The full-text of these studies was examined thoroughly resulting in six RCTs that investigated the efficacy of monoclonal antibodies on the management of patients with CRSwNP.
The study flow diagram is depicted in Figure 1 .
Study characteristics
Six studies fulfilled the inclusion criteria (18) (19) (20) (21) (22) (23) . Αll studies were RCTs and were published between 2006 and 2017. A total of 256 patients were examined in the six RCTs, with 142 of them receiving monoclonal antibodies and 114 placebo. The total number of patients in these studies ranged from 14 to 105. Three of the studies were single-site (19) (20) (21) while the other three were multisite (18, 22, 23) . Subjects were randomized to receive: anti-IL5 therapy with reslizumab (18) or mepolizumab (20, 23) in three studies, anti-IgE therapy with omalizumab in two studies (19, 21) and anti-IL-4Rα therapy with dupilumab in the last RCT (22) . The characteristics of the six included studies as well as baseline demographic and clinical characteristics of the patients are presented in Table 2 and 3.
Risk of Bias Assessment is presented in Figures 2 and 3.
Τotal Nasal Endoscopic Polyp score
The reduction in TPS was assessed in all six studies (Table 4 ).
In five of the six studies the use of monoclonal antibodies was proved effective in reducing nasal polyp burden in patients with CRSwNP. In particular, Gevaert et al. (18) showed that the treatment with 1mg/kg of reslizumab managed to improve the TPSs for up to 12 weeks in 5 of 8 patients. Furthermore, half of the subjects who received a single intravenous infusion of 3mg/kg reslizumab presented a reduction in TPS for 4 weeks. A sub-
Outcomes
The primary outcome of interest in this study was the reduction in total nasal endoscopic polyp score (TPS). Polyps were evaluated on each side by means of nasal endoscopy at each visit and graded based on polyp size resulting in scores of 0 to 4; higher score indicated worse status. TPS was defined as the sum of the left and the right nostril (Table 1) . 
Secondary end points included change in
Statistical analysis
The ultimate objective of this research was to culminate in a quantitative synthesis of the main outcome measures. However, the small number of the included studies, the small sample sizes, the lack of reported data (the effort to communicate with most authors was fruitless) coupled with different outcome measures and follow-ups made it impossible to lead to a metaanalysis.
Results
Literature search
The systematic search in bibliographic databases yielded a number of 1089 studies. Three additional records from trial registries were also identified, two of which were not eligible for the study. After removing duplicates, 803 publications were available for title-abstract screening. Finally, eight articles that could provide data able to answer the research question were group analysis in the study showed that subjects who responded to reslizumab were found to have elevated nasal IL-5 levels at baseline, compared to the non-responders.
Gevaert et al. (20) showed that mepolizumab improved significantly the TPSs in 12 of 20 subjects while no change was shown in the placebo group (p=0,028). However, the subgroup analysis in this study showed that no difference for baseline TPSs and local IL-5 levels was found. Similarly, in the Bachert et al. (23) study, mepolizumab caused a significant improvement in the treatment group as compared to control group from week 9 to week 25.
Concerning omalizumab, Pinto et al. (19) did not manage to show any significant change in TPS in the treatment as compared to placebo group (p<0,58). On the contrary, Gevaert et al. (21) demonstrated that the treatment with omalizumab resulted in significant reduction in TPS compared to placebo (p=0,01 and p=0,99, respectively).
Finally, in the study of Bachert et al. (22) dupilumab showed a significant improvement in TPS in the treatment group as compared to mometasone sprays alone (p<0,001). The difference was seen at week 4 and continued until the end of the treatment period (week 16). In addition, an improvement of at least 1 point in the polyp score was seen in 70% of the dupilumab plus mometasone group conversely to 20% of the subjects in the placebo plus mometasone group.
CT score
The change in CT score was evaluated in four of the six included studies (Table 4 ). Specifically, in three studies the outcome was the improvement in the percentage of sinus opacification in CT images (19, 20) , in one study it was the Lund-Mackay CT score (21) and in the last one both opacification in CT and the Lund-Mackay CT score were computed for the same purpose (22) .
Pinto et al. (17) showed that omalizumab managed to reduce significantly the inflammation compared to the placebo group.
However, the median change of sinus opacification (pre-treatment minus post-treatment) across groups was not statistically significant (p<0,391). On the contrary, Gevaert et al. (19) showed that omalizumab resulted in significant reduction of Lund-Mackay scores on radiologic imaging (p=0,04).
Mepolizumab was effective in improving CT scores in more than half of the treated subjects as opposed to less than 20% in the placebo group (p=0,06, p=0,024, p=0,049 for the 3 different raters of the study) (20) .Finally, in Bachert et al. (22) study a significant improvement from baseline with the use of dupilumab was observed not only in percentage of maxillary sinus opacification (p<0,001) but also in Lund-Mackay total score (p<0,001).
Quality of Life measures
SNOT-20, SNOT-22, SF-36 and Rhinosinusitis Outcome Measurement Instrument (RSOM-31) were included in the secondary measures of most of the six studies (Table 4 ).
In particular, Pinto et al. (19) showed that although omalizumab appeared to improve SNOT-20 scores significantly in the omalizumab as compared to the placebo group, the net change between the two groups was not statistically significant (p<0,78). Concerning the SF-36, vitality was the only domain in which a statistically significant improvement was observed with the use of omalizumab (p<0,05).
In Gevaert et al. (21) study, omalizumab appeared to be effective in improving significantly both the SF-36 (physical health) (p=0,02) and sleep and general symptoms of RSOM-31 (p=0,02).
Finally, SNOT-22 was improved significantly by the use of both dupilumab (22) and mepolizumab (23) (p<0,001 and p=0,005, respectively) (23) .
Nasal airflow (PNIF) and olfaction (UPSIT)
Change in PNIF was the subject of research in four of the included studies (Table 4 ). In Pinto et al. study (19) , omalizumab was not found to be effective in improving PNIF as the net change across the two groups was not statistically significant (p<0,31).
Gevaert et al. (20) reported a reduction in nasal obstraction as patients in the mepolizumab group showed better values from baseline in PNIF as compared to placebo group but the results were not statistically significant (p=0,10). On the contrary, the mean difference between mepolizumab and control group in PNIF values was statisticallly significant (p=0,027, in the second mepolizumab study (23) . At last, Bachert et al. (22) reported a statistically significant mean difference in PNIF for dupilumab group vs placebo (p=0,002).
Three RCTs studied the effectiveness of monoclonal antibodies in olfaction and the outcome was the change in UPSIT score (19, 22, 23) . Neither omalizumab (19) nor mepolizumab (23) was found to yield a statistically significant benefit concerning UPSIT score (p<0,31 and p=0,233, respectively). On the contrary, dupilumab proved to be effective and lead to a statistically significant improvement as compared to placebo (p<0,001) (22) .
Type 2 helper T-cell-associated biomarkers
Concerning changes in Type 2 Helper T-cell-Associated Biomarkers (Table 4) , despite the significant decrease of eosinophil counts which was reported in both treatment groups with the use of reslizumab (18) , a rebound eosinophilia was appeared at week 24 and week 32 in 1mg/kg and 3mg/kg treatment groups, respectively. The use of mepolizumab lead to a significant reduction in blood eosinophil counts compared to placebo group and in this case no rebound eosinophilia effect was reported in any of the two RCTs (20, 23) .
No statistically significant decrease in eosinophil counts was also reported for both dupilumab and placebo group in Bachert et al. (22) study (p=0,78). Finally, in Pinto et al. (19) study omalizumab did not show a significant difference in eosinophils in nasal lavage in either group (p<0,47). Some others biomarkers included in our study are serum IL-5Ra, nasal IL-5Ra, serum ECP, nasal ECP. The changes in values from baseline were studied in two of the six studies. In particular, reslizumab lead to a statistically significant decrease in all these biomarkers in both treatment groups (18) . Lastly, with the exception of nasal ECP (p=0,26), all of the aformentioned biomarkers were significantly decreased by the use of mepolizumab as compared to placebo (20) .
Safety and adverse events
Five RCTs reported a wide variety of adverse events the majority of them were negligible with the most common being upper respiratory tract infections (common cold and nasopharyngitis included). A total number of eight serious adverse events were reported in only two of the included studies none of which was deemed to be associated with the monoclonal antibody therapy (Table 5 ).
Discussion
Since the advent of monoclonal antibodies for the management of several inflammatory conditions, a number of studies have been conducted proposing the potential use of these agents in the treatment of CRSwNP. This is the first systematic review as- Omalizumab is the type of biologic therapy that has been investigated more than any other. The first report for the potential efficacy of this agent in patients with CRSwNP was published by Penn et al. (24) in 2007. In this pilot study, 4 patients with nasal polyposis and comorbid asthma reported a statistically significant difference between the pre and post omalizumab treatment endoscopic scores, which were not combined with statistically relevant differences in their CT scores. This study was followed by a number of other small studies that confirmed the potential clinical benefit of omalizumab (25) (26) (27) . The latter provide low strong evidence and do not allow for definitive conclusions despite their encouraging results. Two systematic reviews have also pointed out the need for further assessment of the effectiveness of anti-IgE therapy in these patients (28, 29) . Aside from the proof of clinical benefit, several other obstacles have to be overcome for omalizumab to be officially incorporated in the standard therapy of CRSwNP. First, cost-effectiveness has not been assessed in any of the aforementioned studies despite its being a crucial factor in the management of this disease. Second, there is not sufficient data regarding the safety of omalizumab; malignancy and anaphylactic reactions are side effects most strongly linked with this biologic agent so far (30, 31) . However, all in all, omalizumab seems to be a safe and tolerable treatment option in patients with moderate-to-severe or severe allergic asthma (32, 33) , a point that is in line with the results of this systematic review.
Based on the present systematic review, anti-IL-5 therapy can be extended to CRSwNP patients (18, 20, 23) . Supporting the results of our systematic review, Castro et al. (34) (35) . An RCT condacted by Laviolette et al. (36) showed that benralizumab lead to a reduction in eosinophil count in the airway mucosa, sputum, bone marrow, and peripheral blood of patients with asthma in comparison to placebo. In addition, a 74% reduction in blood basophil count was also presented showing that this agent could offer a potential benefit in CRSwNP patients who present with elevated levels of this type of cells. However, no study assessing the efficacy of this novel monoclonal antibody in patients with CRSwNP has been conducted so far.
Taking into account the importance of IL-4 and IL-13 cytokines in type 2 inflammatory responses, several studies with monoclonal antibodies, that inhibit either IL-4 or IL-13 have been designed, investigating their efficacy in patients with asthma, with their results however being ambiguous (37) . Dupilumab acts by blocking both cytokines by targeting the a chain of IL-4Ra which is common in both IL-4 and IL-13 and can lead to a more comprehensive inhibition of the type 2 inflammatory pathway.
It has been shown to be of clinical benefit in patients suffering from allergic asthma and atopic dermatitis (16, 17) . Bachert et al.
showed especially encouraging results for the use of dupilumab in patients with CRSwNP as almost all primary and secondary outcomes were met. The results were consistent with those of the aforementioned studies confirming the common type 2 inflammatory mechanisms in these disorders (22) . Consistency was also found with the results of both mepolizumab (20) and omalizumab (21) studies, however no conclusion about the superiority of the one monoclonal antibody over the other can be inferred as all included studies in this systematic review investigated the efficacy of each monoclonal antibody separately against placebo.
The results of this systematic review are liable to certain limitations. First, although we decided to include only RCTs for the sake of the greater power of our research, the low sample size, the short study period, the incomplete reporting data in the majority of them in combination with the heterogeneity among study designs made it difficult to compare the effects of the interventions. Furthermore, we conducted a comprehensive search without language or time limitation in several bibliographic databases and the probability to have missed potential eligible studies is low. However, through our search, we retrieved studies whose results were not available either because their data was still being analyzed (38) or they had not been completed so far (39) (40) (41) . This fact could have an impact on this systematic review or radically change our view regarding this issue in the foreseeable future. of these agents should be taken into account, when deciding on optimal treatment of CRSwNP (42) . Cost-effectiveness of the aforementioned monoclonal antibodies has only been assessed for the conditions, for whom these agents have been approved of. In particular, two studies have shown that benefit outweighs the cost of omalizumab and dupilumab treatment of asthma and atopic dermatitis (43, 44) . It has been found, however, that mepolizumab's cost must be reduced by at least 60% for its use to become cost-effective (45) . No data has been presented regarding cost-effectiveness of these monoclonal antibodies for the treatment of CRSwNP, making it mandatory that further studies evaluate this gravely important aspect. Finally, future research efforts should be directed towards assessing further biomarkers of Th2 inflammatory pathways, which will reflect the response to these novel treatments. A recently studied such biomarker is periostin, the levels of which both in serum and nasal secretions have been found to correlate with the response to anti-inflammatory treatment for CRSwNP (46) .
Conclusions
Targeting IgE, IL-5 and IL-4/IL-13 cytokine pathways constitutes a novel therapy in patients suffering from CRSwNP. Despite the small number of studies, with their small sample size and several limitations, their results are really encouraging and biologic therapy seems to be safe and well tolerated. However, high-quality trials designed to assess these therapeutic alternatives for this specific subpopulation of patients with CRSwNP refractory to standard treatment are called for.
